UK Markets closed


LSE - LSE Delayed price. Currency in EUR
Add to watchlist
10.90-0.41 (-3.64%)
At close: 11:10AM BST


Deutscher Platz 5a
Leipzig 04103
49 341 48792 0

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Jakub Julian BaranChairman of the Management BoardN/AN/AN/A
Mr. Andreas W. SchafhirtChief Financial OfficerN/AN/A1962
Santiago LuengoManaging Director of SecuvitaN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


VITA 34 AG engages in the collection, preparation, cryopreservation, and storage of stem cells from umbilical cord blood and tissue in Europe. The company offers Sibling Initiative that offers free storage of stem cells collected from the umbilical cord blood of a child whose brother or sister is seriously ill and needs the stem cells from the newborn sibling for treatment purposes; VitaPlusDonation that stores stem cells for personal therapeutic stem cell application; and VitaMine&Yours, which combines the storage of umbilical cord blood for personal provision with the possibility of a donation. It also provides Prevention screenings, which enable the detection of genetically related health risks and predispositions; and mobile stem cell team that facilitates the treatment with stem cells from umbilical cord blood in various hospitals. The company was founded in 1997 and is based in Leipzig, Germany.

Corporate governance

VITA 34 AG’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.